OncoLab develops a precision drug delivery (DDS) technology that leverages its biocompatible, nano-gel–based ANGel platform to enable localized and sustained release of macromolecular anticancer therapeutics within tumors. This approach minimizes systemic toxicity while maximizing therapeutic efficacy, opening a new paradigm in cancer treatment.
Founded by a world-class research team from Georgia Tech, OncoLab goes beyond simple drug reformulation to enable novel combination-therapy strategies grounded in deep scientific rigor. The company also possesses scalable manufacturing capabilities suitable for industrial deployment, positioning OncoLab as a rising leader in the next generation of efficacy-driven DDS technologies.
